{"product_id":"devalued-and-distrusted-isbn-9781118487471","title":"Devalued and Distrusted","description":"\u003cp\u003e\u003cb\u003eAn expert's view on solving the challenges confronting today's pharmaceutical industry\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAuthor John LaMattina, a thirty-year veteran of the pharmaceutical industry and former president of Pfizer's Global R\u0026amp;D Division, is internationally recognized as an expert on the pharmaceutical industry. His first book, \u003ci\u003eDrug Truths: Dispelling the Myths About Pharma R\u0026amp;D,\u003c\/i\u003e was critically acclaimed for clearing up misconceptions about the pharmaceutical industry and providing an honest account of the contributions of pharmaceutical research and development to human health and well-being.\u003c\/p\u003e \u003cp\u003eAs he toured the country discussing \u003ci\u003eDrug Truths,\u003c\/i\u003e Dr. LaMattina regularly came across people who were filled with anger, accusing the pharmaceutical industry of making up diseases, hiding dangerous side effects, and more. This book was written in response to that experience, critically examining public perceptions and industry realities.\u003c\/p\u003e \u003cp\u003eStarting with \"4 Secrets that Drug Companies Don't Want You to Know,\" \u003ci\u003eDevalued and Distrusted\u003c\/i\u003e provides a fact-based account of how the pharmaceutical industry works and the challenges it faces. It addresses such critical issues as:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eWhy pharmaceutical R\u0026amp;D productivity has declined\u003c\/li\u003e \u003cli\u003eWhere pharmaceutical companies need to invest their resources\u003c\/li\u003e \u003cli\u003eWhat can be done to solve core health challenges, including cancer, diabetes, and neurodegenerative diseases\u003c\/li\u003e \u003cli\u003eHow the pharmaceutical industry can regain public trust and resuscitate its image\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eOur understanding of human health and disease grows daily; however, converting science into medicine is increasingly challenging. Reading \u003ci\u003eDevalued and Distrusted,\u003c\/i\u003e you'll not only gain a greater appreciation of those challenges, but also the role that the pharmaceutical industry currently plays and can play in solving those challenges.\u003cbr\u003e \u003cbr\u003e \u003cbr\u003e \u003cb\u003eGet to know the author:\u003c\/b\u003e Read an interview with John LaMattina or watch a video on ChemistryViews!\u003cbr\u003e \u003cbr\u003e \u003ca href=\"http:\/\/www.chemistryviews.org\/details\/ezine\/4286441\/John_LaMattina_30_Years_in_Pharma.html\"\u003e\u003cb\u003eInterview:\u003c\/b\u003e John LaMattina: 30 Years in Pharma\u003c\/a\u003e\u003cbr\u003e \u003cbr\u003e \u003ca href=\"http:\/\/www.chemistryviews.org\/details\/video\/4498851\/Can_the_Pharmaceutical_Industry_Restore_its_Broken_Image.html\"\u003e\u003cb\u003eVideo: \u003c\/b\u003eCan the Pharmaceutical Industry Restory its Broken Image?\u003c\/a\u003e\u003c\/p\u003e  \u003cp\u003eACKNOWLEDGMENTS ix\u003c\/p\u003e \u003cp\u003eINTRODUCTION 1\u003c\/p\u003e \u003cp\u003eCHAPTER 1 THE FOUR SECRETS THE DRUG COMPANIES DON’T WANT YOU TO KNOW 4\u003c\/p\u003e \u003cp\u003eDrug Companies Underestimate Dangerous Side Effects 5\u003c\/p\u003e \u003cp\u003eDrug Companies Control Much of the Information Your Doctor Gets 10\u003c\/p\u003e \u003cp\u003eYou’re Often Prescribed Drugs That You Don’t Need 14\u003c\/p\u003e \u003cp\u003eDrugs Target the Symptoms, Not the Cause 19\u003c\/p\u003e \u003cp\u003eConclusion 22\u003c\/p\u003e \u003cp\u003eReferences 23\u003c\/p\u003e \u003cp\u003eCHAPTER 2 WHAT HAS HAPPENED TO R\u0026amp;D PRODUCTIVITY? 25\u003c\/p\u003e \u003cp\u003eImpact of Mergers on R\u0026amp;D Productivity 26\u003c\/p\u003e \u003cp\u003eHeightened FDA Requirements for NDAs 34\u003c\/p\u003e \u003cp\u003eHigher Hurdles Set by Payers 41\u003c\/p\u003e \u003cp\u003eConclusion 46\u003c\/p\u003e \u003cp\u003eReferences 48\u003c\/p\u003e \u003cp\u003eCHAPTER 3 KEY THERAPEUTIC AREAS FOR IMPROVING HEALTH 49\u003c\/p\u003e \u003cp\u003eCancer 51\u003c\/p\u003e \u003cp\u003eDiseases of the Brain 54\u003c\/p\u003e \u003cp\u003eCardiovascular Disease (CVD) 60\u003c\/p\u003e \u003cp\u003eDiabetes 63\u003c\/p\u003e \u003cp\u003eBacterial Infections 65\u003c\/p\u003e \u003cp\u003eConclusion 68\u003c\/p\u003e \u003cp\u003eReferences 69\u003c\/p\u003e \u003cp\u003eCHAPTER 4 IMPROVING R\u0026amp;D OUTPUT 71\u003c\/p\u003e \u003cp\u003eThe Views of Others 72\u003c\/p\u003e \u003cp\u003ePharma’s Blockbuster Mentality Needs to Change 72\u003c\/p\u003e \u003cp\u003eCan “Predictive Innovation” Lead to Greater Success Rates? 76\u003c\/p\u003e \u003cp\u003eWould Royalties Make Scientists More Productive? 78\u003c\/p\u003e \u003cp\u003eWill Drug Repositioning Help Fill the R\u0026amp;D Pipeline? 80\u003c\/p\u003e \u003cp\u003eConsultants Don’t Always Have the Facts 82\u003c\/p\u003e \u003cp\u003ePersonal Views 84\u003c\/p\u003e \u003cp\u003eDiscovery Must Focus on Productivity 85\u003c\/p\u003e \u003cp\u003eDoes Size Help or Hinder R\u0026amp;D Productivity? 87\u003c\/p\u003e \u003cp\u003eTo Outsource or Not to Outsource? That’s the Pharma R\u0026amp;D Question 89\u003c\/p\u003e \u003cp\u003eBig Pharma Early Research Collaborations 92\u003c\/p\u003e \u003cp\u003eConclusion 93\u003c\/p\u003e \u003cp\u003eReferences 95\u003c\/p\u003e \u003cp\u003eCHAPTER 5 RESTORING PHARMA’S IMAGE 96\u003c\/p\u003e \u003cp\u003eIllegal Detailing of Drugs 97\u003c\/p\u003e \u003cp\u003ePharmaceutical Companies Should Drop TV Ads 98\u003c\/p\u003e \u003cp\u003eThe Need for Greater Transparency 100\u003c\/p\u003e \u003cp\u003eHow Committed Is Big Pharma to Rare Diseases? 102\u003c\/p\u003e \u003cp\u003ePharmaceutical Companies and Philanthropy 104\u003c\/p\u003e \u003cp\u003ePharma Needs to Have Its Scientists Tell Their Stories 105\u003c\/p\u003e \u003cp\u003eConclusion 106\u003c\/p\u003e \u003cp\u003eReferences 107\u003c\/p\u003e \u003cp\u003eCHAPTER 6 FINAL THOUGHTS 109\u003c\/p\u003e \u003cp\u003eReferences 114\u003c\/p\u003e \u003cp\u003eINDEX 115\u003c\/p\u003e  \u003cp\u003e\"Oz should invite LaMattina back on his show.  Since LaMattina treats all concerns respectfully, Oz needn’t worry about feeling devalued or distrusted.\"  (\u003ci\u003eBarron's\u003c\/i\u003e, 5 May 2014)\u003c\/p\u003e \u003cp\u003e“This is an honest book by an insider who believes in the basic good that the industry does.”  (\u003ci\u003eThe Quarterly Review of Biology\u003c\/i\u003e, 1 September 2013)\u003c\/p\u003e \u003cp\u003e“Summing Up:  Recommended.  General audiences.”  (\u003ci\u003eChoice\u003c\/i\u003e, 1 September 2013)\u003c\/p\u003e \u003cp\u003e“For those more loosely associated or aspiring to work with in it, I particularly recommend this book as a balanced and informative read on the pressures the industry faces. It should also provide the basis for more reasoned argument and forewarn anyone else potentially ambushed by a TV show.”  (\u003ci\u003eChemMedChem\u003c\/i\u003e, 19 July 2013)\u003c\/p\u003e \u003cp\u003e“That said, the suggestions made by LaMattina for improvements in productivity and transparency are timely, and the book makes interesting if unexciting reading.”  (\u003ci\u003eChemistry \u0026amp; Industry\u003c\/i\u003e, 1 June 2013)\u003c\/p\u003e \u003cp\u003e“John LaMattina (ex-head of Pfizer's global R\u0026amp;D) has a new book out about the industry, called \u003ca href=\"http:\/\/www.amazon.com\/gp\/product\/B00ANR91W8\/ref=as_li_ss_tl?ie=UTF8\u0026amp;tag=lagniappe-20\u0026amp;linkCode=as2\u0026amp;camp=1789\u0026amp;creative=390957\u0026amp;creativeASIN=B00ANR91W8\"\u003eDevalued and Distrusted\u003c\/a\u003e.  He \u003ca href=\"http:\/\/www.pharmalot.com\/2012\/12\/repairing-a-broken-pharma-image-lamattina-explains\/\"\u003etells \u003ci\u003ePharmalot\u003c\/i\u003e\u003c\/a\u003e that he got the idea to write a sequel to his earlier book, \u003ca href=\"http:\/\/www.amazon.com\/gp\/product\/0470393181\/ref=as_li_ss_tl?ie=UTF8\u0026amp;tag=lagniappe-20\u0026amp;linkCode=as2\u0026amp;camp=1789\u0026amp;creative=390957\u0026amp;creativeASIN=0470393181\"\u003eDrug Truths\u003c\/a\u003e, when he appeared on the \"Dr. Oz\" show.”  (\u003ci\u003eIn The Pipeline\u003c\/i\u003e, 1 December 2012)\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e  \u003cp\u003e\u003cb\u003eJOHN L. LaMATTINA, PHD,\u003c\/b\u003e retired as president of Pfizer's Global Research and Development in 2007, where he managed more than 13,000 scientists and support professionals in the United States, Europe, and Asia. Dr. LaMattina has received numerous honors and awards, including an Honorary Doctor of Science from the University of New Hampshire. Currently a Senior Partner with PureTech Ventures, he is the author of \u003ci\u003eDrug Truths: Dispelling the Myths About Pharma R\u0026amp;D\u003c\/i\u003e (Wiley).\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAn expert's view on solving the challenges confronting today's pharmaceutical industry\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAuthor John LaMattina, a thirty-year veteran of the pharmaceutical industry and former president of Pfizer's Global R\u0026amp;D Division, is internationally recognized as an expert on the pharmaceutical industry. His first book, \u003ci\u003eDrug Truths: Dispelling the Myths About Pharma R\u0026amp;D,\u003c\/i\u003e was critically acclaimed for clearing up misconceptions about the pharmaceutical industry and providing an honest account of the contributions of pharmaceutical research and development to human health and well-being.\u003c\/p\u003e \u003cp\u003eAs he toured the country discussing \u003ci\u003eDrug Truths,\u003c\/i\u003e Dr. LaMattina regularly came across people who were filled with anger, accusing the pharmaceutical industry of making up diseases, hiding dangerous side effects, and more. This book was written in response to that experience, critically examining public perceptions and industry realities.\u003c\/p\u003e \u003cp\u003eStarting with \"4 Secrets that Drug Companies Don't Want You to Know,\" \u003ci\u003eDevalued and Distrusted\u003c\/i\u003e provides a fact-based account of how the pharmaceutical industry works and the challenges it faces. It addresses such critical issues as:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eWhy pharmaceutical R\u0026amp;D productivity has declined\u003c\/li\u003e \u003cli\u003eWhere pharmaceutical companies need to invest their resources\u003c\/li\u003e \u003cli\u003eWhat can be done to solve core health challenges, including cancer, diabetes, and neurodegenerative diseases\u003c\/li\u003e \u003cli\u003eHow the pharmaceutical industry can regain public trust and resuscitate its image\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eOur understanding of human health and disease grows daily; however, converting science into medicine is increasingly challenging. Reading \u003ci\u003eDevalued and Distrusted,\u003c\/i\u003e you'll not only gain a greater appreciation of those challenges, but also the role that the pharmaceutical industry currently plays and can play in solving those challenges.\u003c\/p\u003e  \u003cp\u003e“ … the book is laden with so many facts, critical insights and pearls of wisdom that it deserves the attention of a wide audience, from lay people to professionals in R\u0026amp;D, medicine, government, business and mass media. Dr. LaMatina has performed a public service by drawing on his broad experience to clarify the issues and the many challenges that have to be faced if progress in therapeutic molecular medicine is to continue, and to illuminate the ongoing tensions that are bound to arise with ever increasing risks and costs in pharma and biotech R\u0026amp;D, never-perfect new medicines and constantly rising consumer expectations and government involvement.”—\u003cb\u003e\u003ci\u003eE J Corey\u003c\/i\u003e\u003c\/b\u003e, Harvard University\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989051916517,"sku":"NP9781118487471","price":35.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781118487471.jpg?v=1761782593","url":"https:\/\/k12savings.com\/products\/devalued-and-distrusted-isbn-9781118487471","provider":"K12savings","version":"1.0","type":"link"}